77 unknown, 56 completed, 23 recruiting, 15 terminated. 81 Phase 2, 42 Phase 3, 41 Not applicable, 19 Phase 1, 8 Phase 4.
Follow TACE: new trials by email Literature Review of TACE trials Research Report on TACE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer AK112, Irinotecan, Cisplatin - Neuroendocrine Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 56 | 2026-08-01 | 2026-07-17 |
| Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma TACE, SBRT - Hepatocellular Carcinoma Non-resectable | Not applicable | Recruiting | RWTH Aachen University | 30 | 2026-05-05 | 2026-05-11 |
| TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk sintilimab, ipilimumab N01, Lenvatinib - Hepato Cellular Carcinoma (HCC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 105 | 2026-03-18 | 2026-03-27 |
| 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer 177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE) - Metastatic Prostate Cancer, Prostate Cancer | Phase 1 | Recruiting | University of California, San Francisco | 30 | 2026-03-16 | 2026-06-01 |
| H101 Plus TACE for r/m HNSCC H101, TACE - Head and Neck Squamous Cell Carcinoma, Oncolytic Virus | Phase 2 | Recruiting | West China Hospital | 20 | 2026-03-02 | 2026-07-17 |
| TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma TACE, HAIC, PD-1inhibitors - HCC | Not yet recruiting | Tongji Hospital | 364 | 2026-01-31 | 2026-01-14 | |
| A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma Apatinib, Camrelizumab, TACE - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Zhongshan Hospital | 222 | 2025-12-22 | 2025-12-30 |
| GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, TACE - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 2 | Recruiting | Beijing Gene Key Life Technology Co., Ltd | 48 | 2025-11-14 | 2026-08-17 |
| TACE Treats Nodular Goiter TACE - Nodular Goiter | Not applicable | Enrolling by invitation | Peking Union Medical College Hospital | 30 | 2025-09-01 | 2025-12-02 |
| TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment PD-1 inhibitor, TACE - Hepatocellular Carcinoma | Recruiting | Fudan University | 50 | 2025-08-15 | 2025-08-17 | |
| A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma HAI-FOLFOX + bevacizumab + QL1706, TACE + bevacizumab + TAS-102 + QL1706 - Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | Active not recruiting | Sun Yat-sen University | 62 | 2025-08-01 | 2026-04-29 |
| Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC Sintilimab, radiotherapy, TACE - Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 286 | 2025-07-10 | 2025-09-22 |
| Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma TACE, Sintilimab combined with Bevacizumab, individualized anti-tumor new antigen iNeo-Vac-R01 injection - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | Zhejiang University | 30 | 2025-04-09 | 2025-05-29 |
| Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma Lenvatinib, Pembrolizumab, Icaritin soft capsules, TACE - Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Zhiyong Huang | 60 | 2025-04-01 | 2025-03-26 |
| A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. tirapazamine, Transarterial Embolization (TAE), TACE - HCC | Phase 2 / Phase 3 | Recruiting | Zhejiang Raygene Pharmaceuticals Co., Ltd | 300 | 2025-03-27 | 2025-04-06 |
| ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC Lenvatinib, Pembrolizumab, Atezolizumab - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 300 | 2025-02-19 | 2025-12-01 |
| A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE - HCC | Not applicable | Active not recruiting | Tongji Hospital | 130 | 2025-02-10 | 2025-06-06 |
| TACE Combined Surgery for the Resectable Huge HCC TACE, Surgery - Hepatocellular Carcinoma, Hepatic Chemotherapy | Recruiting | Sun Yat-sen University | 326 | 2025-01-01 | 2025-04-03 | |
| TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma TACE, Lenvatinib, PD-1 Inhibitors - Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization | Not applicable | Recruiting | Sun Yat-sen University | 32 | 2024-12-13 | 2025-08-14 |
Showing 20 of 194. Sign in to see all of them.
Carcinoma, Hepatocellular (142) · Liver Neoplasms (28) · Recurrence (4) · Cholangiocarcinoma (3) · Biliary Tract Neoplasms (2) · Carcinoma (2) · Colorectal Neoplasms (2) · Hepatitis B (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Adenocarcinoma (1) · Bicuspid Aortic Valve Disease (1) · Bile Duct Neoplasms (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1)
Sun Yat-sen University (22) · Eastern Hepatobiliary Surgery Hospital (13) · Fudan University (11) · Shanghai Zhongshan Hospital (9) · Zhongda Hospital (6) · Zhejiang University (5) · Zhejiang Cancer Hospital (4) · Beijing Tsinghua Chang Gung Hospital (3) · Chinese University of Hong Kong (3) · National Cancer Institute (NCI) (3) · Peking Union Medical College Hospital (3) · Seoul National University Hospital (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Tongji Hospital (3) · Abramson Cancer Center at Penn Medicine (2)
China (123) · United States (26) · Hong Kong (7) · Italy (7) · Germany (6) · Taiwan (6) · Japan (5) · South Korea (5) · Belgium (4) · France (4) · Canada (3) · Egypt (3) · Spain (3) · Australia (2) · Austria (2)
Feng Duan, MD (3) · Gao-Jun Teng, M.D. (3) · Peng Wang, MD (3) · Shen Feng, MD (3) · Tim F Greten, M.D. (3) · Gao-Jun Teng, MD (2) · Gaojun Teng, MD (2) · Guoliang Shao, MD (2) · Ming Kuang, Ph.D. (2) · Ming Kuang, PhD (2) · Ming Shi, MD (2) · Ming Zhao, doctor (2) · Zheng-Gang Ren, M.D. (2) · Abdelrahman Zekri, Professor (1)
PMID 23269991, PMID 32557715, PMID 14667750, PMID 15915370, PMID 16557381, PMID 22424438, PMID 23426336, PMID 23508822, PMID 23874536, PMID 24126369, PMID 24420729, PMID 24650695, PMID 25450210, PMID 26871639, PMID 27816492, PMID 28923358, PMID 29420221, PMID 29433850, PMID 30016989, PMID 30578687, PMID 30688989, PMID 31801872, PMID 32111770, PMID 32163181, PMID 32712254, PMID 33300372, PMID 33510460, PMID 33611431, PMID 34926296, PMID 34982369, PMID 35119481, PMID 35421228, PMID 35643250, PMID 35921605, PMID 35978604, PMID 36421345, PMID 36529152, PMID 36750721, PMID 36937990, PMID 37038986, PMID 37097715, PMID 37368105, PMID 37400162, PMID 37611799, PMID 38205877, PMID 38568599, PMID 38745965, PMID 38900435, PMID 39279973, PMID 39384742
2017 (1), 2019 (1), P30CA033572 (1), P30CA043703 (1), P30CA124435 (1), R01CA194307 (1), U10CA021115 (1)